Summit Therapeutics Inc.
SMMT
Jodie situation report
Summit Therapeutics Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- Quarterly and YTD increases in clinical-trial spending for HARMONi-3, HARMONi-7 and HARMONi-GI3 driven by higher enrollment and related materials purchases.
- Newly disclosed clinical trial collaboration with Arcus to evaluate ivonescimab plus casdatifan in clear cell renal cell carcinoma.
Invalidation: The isolated read changes if SMMT's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind SMMT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
RVMDRevolution Medicines, Inc.partnerApr 30, 2026 ▾
“Other Collaboration Agreements 22 In June 2025, the Company entered into a clinical trial collaboration with Revolution Medicines Inc.”
Depended on by
CBIOCrescent Biopharma, Inc.competitorApr 29, 2026 ▾
“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics Inc., BioNTech SE, LaNova Medi…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
SMMT is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.